Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes.
Fiche publication
Date publication
décembre 2015
Journal
Canadian journal of physiology and pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGELY Catherine
Tous les auteurs :
Rochette L, Ghibu S, Muresan A, Vergely C
Lien Pubmed
Résumé
Diabetes is a chronic metabolic disease with a high prevalence worldwide. Diabetes and insulin resistance are associated with the development of cardiovascular and nervous diseases. The development of these disorders reflects complex pathological processes in which the oxidative stress caused by reactive oxygen species (ROS) and reactive nitrogen species (RNS) plays a pivotal role. It is widely accepted that diabetes impairs endothelial nitric oxide synthase (eNOS) activity and increases the production of ROS, thus resulting in diminished NO bioavailability and increased oxidative stress. Alpha-lipoic acid (LA) possesses beneficial effects both in the prevention and in the treatment of diabetes. LA is a potent antioxidant with insulin-mimetic and anti-inflammatory activity. LA in the diet is quickly absorbed, transported to the intracellular compartments, and reduced to dihydrolipoic acid (DHLA) under the action of enzymes. LA, which plays an essential role in mitochondrial bioenergetic reactions, has drawn considerable attention as an antioxidant for use in managing diabetic complications such as retinopathy, neuropathy and other vascular diseases.
Mots clés
Animals, Antioxidants, metabolism, Diabetes Mellitus, drug therapy, Humans, Mitochondria, drug effects, Oxidative Stress, drug effects, Reactive Nitrogen Species, metabolism, Reactive Oxygen Species, metabolism, Thioctic Acid, analogs & derivatives
Référence
Can. J. Physiol. Pharmacol.. 2015 Dec;93(12):1021-7